Catabasis Pharmaceuticals : FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich’s Ataxi

The Friedreich’s Ataxia Research Alliance (FARA) and Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) bring to the notice of the public that Catabasis Pharmaceuticals is the receiver of the Kyle Bryant Translational Research Award. Catabasis is a clinical-theatre drug development company built on a path pharmacology technology platform. The two year grant will be for the Evaluation of CAT-4001 in Frataxin-deficient mouse models and dorsal root ganglia neurons to empower its therapeutic development for Friedreich’s ataxia. This operate will be led by Dr. Andrew Nichols at Catabasis along with collaborators Dr. Mark Payne at Indiana University and Dr. Jordi Magrane at Weill Cornell College of Medicine who are expected to bring to pass testing in the Friedreich’s ataxia (FA) creature models.

Catabasis is developing CAT-4001 because a potential treatment for neurodegenerative diseases similar as FA. CAT-4001 is designed to activate Nrf2 and stop NF-kB, both of which are implicated in FA pathophysiology. Catabasis has shown that CAT-4001 modulates the Nrf2 and NF-kB pathways in the two cellular assays and animal models.

“We are excited to verify this research as it brings a in posse new candidate to the FA handling pipeline and the research development team advancing the labor is an example of FARA’s solitary public partnership strategy. We believe that we versify the most meaningful research advancements while FARA, our academic investigators and our pharmaceutical partners take a collaborative come to answering research questions,” before-mentioned FARA Executive Director, Jennifer Farmer.

The Kyle Bryant Translational Research Award specifically focuses up~ the body pre-clinical and clinical investigations that target treatments for FA. The bestowal is named for a young individual diagnosed in his early teens by FA, Kyle Bryant, who started a cycling program called rideATAXIA with his family in 2007. The named adjudication not only honors Kyle’s power to originate to do his part to advance FA research but also recognizes wholly FA families involved in fundraising for research.

“We greatly appreciate the stay of the Friedreich’s Ataxia Research Alliance since we advance the preclinical development of CAT-4001 because a candidate to treat FA,” related Andrew Nichols, PhD, Catabasis Senior Vice President, Research and Non-Clinical Development. “We are sentient to the unmet medical need on this account that patients affected by Friedreich’s ataxia and believe partnerships such as this could complete a meaningful difference in discovering and developing therapies conducive to them.”

About FA

Friedreich’s ataxia is a thin, degenerative, life-shortening neuro-muscular malady that affects children and adults, and involves the forfeiture of strength and coordination usually chief to wheelchair use; diminished vision, opportunity to be heard and speech; scoliosis (curvature of the spinal column); increased risk of diabetes; and a life-minatory heart condition. There are no FDA-approved treatments.

About FARA

The Friedreich’s Ataxia Research Alliance (FARA) is a 501(c)(3), non-bring good, charitable organization dedicated to accelerating scrutiny leading to treatments and a antidote for Friedreich’s ataxia. www.CureFA.org

About CAT-4001

Catabasis is developing CAT-4001 in the same manner with a potential treatment for neurodegenerative diseases of that kind as Friedreich’s ataxia (FA) and amyotrophic lateral sclerosis (ALS). CAT-4001 is a narrow molecule that activates Nrf2 and inhibits NF-kB, pair pathways that have been implicated in FA and ALS. Catabasis has shown that CAT-4001 modulates the Nrf2 and NF-kB pathways in both cellular assays and animal models.

About Catabasis

Catabasis Pharmaceuticals is a clinical-step biopharmaceutical company focused on the ascertainment, development and commercialization of novel therapeutics using its see preprinter Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company’s SMART linker technology platform is based attached the concept of treating diseases ~ means of simultaneously modulating multiple targets in single or more related disease pathways. The Company engineers bi-functional ~ion candidates that are conjugates of brace molecules, or bioactives, each with known pharmacological agility, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved preservation and tolerability. The Company’s point of concentration is on treatments for rare diseases. The Company is also developing other product candidates for the usage of serious lipid disorders. For added information on the Company’s technology and pipeline of mix with ~s candidates, please visit www.catabasis.com.

View cause version on businesswire.com: http://www.businesswire.com/word/home/20160119005239/en/

Among them is preceding Fed Chairman Alan Greenspan, who had recanted his conviction in free market economics early in the sadness.

Recent Comments

    Archives